Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Withdrawn 2Recruiting 1No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Adenocarcinoma of Lung 2Neoplasm Metastasis 1Carcinoma 1

Interventions

Paclitaxel 6Radiotherapy 5Carboplatin 5capmatinib 2Radiosurgery 2Gemcitabine 2tetrathiomolybdate 1spartalizumab 1pembrolizumab 1palbociclib 1onartuzumab 1nintedanib 1fludarabine phosphate 1fludarabine 1efaproxiral 1durvalumab 1binimetinib 1aldesleukin 1Vinorelbine 1Technetium Tc 99m Sestamibi 1Taxes 1Sorafenib 1Platinum 1Nivolumab 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunotherapy 1Immunoenzyme Techniques 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Adenocarcinoma of Lung × capmatinib × Clear all
NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Novartis

Phase 2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03240393 2018-07-26

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Novartis

Phase 2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡